0000000000189943

AUTHOR

Vladimir Shalgunov

0000-0001-8956-1207

showing 7 related works from this author

Trans -Cyclooctene-Functionalized PeptoBrushes with Improved Reaction Kinetics of the Tetrazine Ligation for Pretargeted Nuclear Imaging

2020

Tumor targeting using agents with slow pharmacokinetics represents a major challenge in nuclear imaging and targeted radionuclide therapy as they most often result in low imaging contrast and high radiation dose to healthy tissue. To address this challenge, we developed a polymer-based targeting agent that can be used for pretargeted imaging and thus separates tumor accumulation from the imaging step in time. The developed targeting agent is based on polypeptide-graft-polypeptoid polymers (PeptoBrushes) functionalized with trans-cyclooctene (TCO). The complementary In-111-labeled imaging agent is a 1,2,4,5-tetrazine derivative, which can react with aforementioned TCO-modified PeptoBrushes i…

pretargeted imagingGeneral Physics and Astronomy02 engineering and technology010402 general chemistry01 natural sciencesArticlechemistry.chemical_compoundTetrazinetetrazine ligationCycloocteneGeneral Materials Sciencepolypeptide-graft-polypeptoidsPretargetingchemistry.chemical_classificationGeneral EngineeringPolymerEPR effectPeptoBrush021001 nanoscience & nanotechnologynanomedicineSmall moleculeCombinatorial chemistryImaging agent0104 chemical scienceschemistrySPECTNanomedicineBioorthogonal chemistry0210 nano-technologyACS Nano
researchProduct

Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET

2015

Dopamine D2/3 receptor (D2/3R) agonist PET tracers are better suited for the imaging of synaptic dopaminergic neurotransmission than D2/3R antagonists and may also offer the opportunity to study in vivo the high-affinity state of D2/3R (D2/3RHigh). With the aim to develop 18F-labeled D2/3R agonists suitable for widespread clinical application, we report here on the synthesis and in vitro and in vivo evaluation of a D2/3R agonist ligand from the aminomethyl chromane (AMC) class-(R)-2-[(4- 18Fluorobenzylamino)methyl]chroman-7-ol (18F-AMC20). Methods: In vitro affinities of AMC20 toward dopaminergic receptor subtypes were measured in membrane homogenates prepared from HEK293 cells expressing h…

MaleBenzylaminesChemistry Techniques SyntheticPharmacologyLigandsRats Sprague-DawleyCricetinaeBINDINGRadioligandIN-VIVORacloprideRadiochemistryChemistryDopaminergicBrainStereoisomerismLigand (biochemistry)SERIESADDICTIONDopamine receptorDopamine AgonistsHIGH-AFFINITY STATEmedicine.drugAgonistmedicine.drug_classDRUG-ABUSECHO CellsPOSITRON-EMISSION-TOMOGRAPHYCricetulusFIn vivoDopamine receptor D2medicineAnimalsHumansRadiology Nuclear Medicine and imagingBenzopyransChromansReceptors Dopamine D2F-18Receptors Dopamine D3Biological TransportAgonist tracerRatsKineticsHEK293 CellsPETDopamine receptorRaclopridePositron-Emission TomographyRADIOTRACERSYSTEMJournal of Nuclear Medicine
researchProduct

Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emissi…

2019

Abstract The concept of the high‐affinity state postulates that a certain subset of G‐protein‐coupled receptors is primarily responsible for receptor signaling in the living brain. Assessing the abundance of this subset is thus potentially highly relevant for studies concerning the responses of neurotransmission to pharmacological or physiological stimuli and the dysregulation of neurotransmission in neurological or psychiatric disorders. The high‐affinity state is preferentially recognized by agonists in vitro. For this reason, agonist tracers have been developed as tools for the noninvasive imaging of the high‐affinity state with positron emission tomography (PET). This review provides an…

Central Nervous SystemBETA-ADRENERGIC-RECEPTORpositron emission tomographyagonist high-affinity stateD-2/3 AGONISTG-protein-coupled receptorsReview ArticleReceptors G-Protein-Coupledchemistry.chemical_compound0302 clinical medicineDrug DiscoveryReceptorNeurotransmitterReview Articles0303 health sciencesmedicine.diagnostic_testNONHUMAN PRIMATE BRAINEndocytosisTEST-RETEST REPRODUCIBILITYPositron emission tomographyG‐protein‐coupled receptors030220 oncology & carcinogenesisENDOGENOUS OPIOID RELEASEMolecular MedicineIN-VIVO BINDINGSignal TransductionAgonistNoninvasive imagingexperimental designmedicine.drug_classNeurotransmissionRAT-BRAINneurotransmittersagonist high‐affinity state03 medical and health sciencesIn vivomedicineAnimalsHumanshuman brain030304 developmental biologyG protein-coupled receptorPharmacologyDOPAMINE D2(HIGH) RECEPTORS5-HT1A RECEPTORSchemistryPositron-Emission TomographyPET RADIOLIGANDRadiopharmaceuticalsNeuroscienceMedicinal research reviews
researchProduct

Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu

2021

Introduction: Radiotherapy of cancer requires both alpha- and beta-particle emitting radionuclides, as these radionuclide types are efficient at destroying different types of tumors. Both classes of radionuclides require a vehicle, such as an antibody or a polymer, to be delivered and retained within the tumor. Polyglutamic acid (pGlu) is a polymer that has proven itself effective as a basis of drug-polymer conjugates in the clinic, while its derivatives have been used for pretargeted tumor imaging in a research setup. trans-Cyclooctene (TCO) modified pGlu is suitable for pretargeted imaging or therapy, as well as for intratumoral radionuclide therapy. In all cases, it becomes indirectly ra…

0303 health sciencesCancer ResearchAlpha Particle EmitterPolyglutamic acidRadiochemistrySize-exclusion chromatographyPolypeptidesPolyethylene glycolTargeted radionuclide therapyAc030218 nuclear medicine & medical imagingTetrazine ligation03 medical and health scienceschemistry.chemical_compoundTetrazine0302 clinical medicineIon bindingchemistryRadionuclide therapyClick chemistryLuMolecular MedicineDOTARadiology Nuclear Medicine and imaging030304 developmental biology
researchProduct

Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging

2019

Pretargeted nuclear imaging based on the ligation between tetrazines and nano-sized targeting agents functionalized with trans-cyclooctene (TCO) has recently been shown to improve both imaging contrast and dosimetry in nuclear imaging of nanomedicines. Herein, we describe the improved radiosynthesis of a 11 C-labeled tetrazine ([ 11 C]AE-1) and its preliminary evaluation in both mice and pigs. Pretargeted imaging in mice was carried out using both a new TCO-functionalized polyglutamic acid and a previously reported TCO-functionalized bisphosphonate system as targeting agents. Unfortunately, pretargeted imaging was not successful using these targeting agents in pair with [ 11 C]AE-1. Howeve…

Nuclear imagingClinical BiochemistryTetrazinePET imagingPharmaceutical ScienceCarbon-1101 natural sciencesBiochemistryTetrazinechemistry.chemical_compoundIn vivoTrans-cycloocteneDrug DiscoveryMolecular BiologyPretargetingPretargeting010405 organic chemistryChemistryOrganic ChemistryRadiosynthesisPet imaging3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryMolecular MedicineBiomedical engineeringBioorganic & Medicinal Chemistry Letters
researchProduct

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their…

2014

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived […

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drugJournal of Medicinal Chemistry
researchProduct

On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion

2021

Radiochemical conversion is an important term to be included in the "Consensus nomenclature rules for radiopharmaceutical chemistry". Radiochemical conversion should be used to define reaction efficiency by measuring the transformation of components in a crude reaction mixture at a given time, whereas radiochemical yield is better suited to define the efficiency of an entire reaction process including, for example, separation, isolation, filtration, and formulation. (C) 2020 Elsevier Inc. All rights reserved.

Cancer ResearchRadiochemistryNomenclatureRadiochemical conversionChemistryRadiochemistry610 Medicine & health10181 Clinic for Nuclear MedicineTerminology030218 nuclear medicine & medical imagingNuclear chemistryRadiochemical yield03 medical and health sciences0302 clinical medicineddc:5701313 Molecular Medicine030220 oncology & carcinogenesisYield (chemistry)2741 Radiology Nuclear Medicine and ImagingMolecular Medicine1306 Cancer ResearchRadiology Nuclear Medicine and imagingRadiopharmaceutical sciencesConsensus guidelinesNuclear Medicine and Biology
researchProduct